Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 5.9% in August

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 4,300,000 shares, a growth of 5.9% from the August 15th total of 4,060,000 shares. Based on an average daily volume of 267,200 shares, the days-to-cover ratio is presently 16.1 days. Currently, 21.4% of the company’s shares are short sold.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of Dianthus Therapeutics by 250.0% during the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after acquiring an additional 384,182 shares in the last quarter. Octagon Capital Advisors LP increased its holdings in shares of Dianthus Therapeutics by 15.4% in the fourth quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after purchasing an additional 74,000 shares during the period. Vestal Point Capital LP bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth $1,404,000. SG Americas Securities LLC bought a new position in shares of Dianthus Therapeutics in the second quarter worth $112,000. Finally, Janus Henderson Group PLC bought a new position in shares of Dianthus Therapeutics in the first quarter worth $11,251,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, August 12th. Cantor Fitzgerald assumed coverage on Dianthus Therapeutics in a research report on Thursday, June 27th. They issued an “overweight” rating for the company. Wedbush decreased their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Finally, Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Buy” and an average price target of $44.71.

Dianthus Therapeutics Stock Performance

DNTH traded down $0.43 during midday trading on Tuesday, reaching $25.99. 189,056 shares of the company were exchanged, compared to its average volume of 186,213. The company’s fifty day moving average price is $28.12 and its 200 day moving average price is $26.11. The company has a market cap of $762.81 million, a price-to-earnings ratio of -4.46 and a beta of 1.85. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. The business had revenue of $1.86 million during the quarter, compared to analysts’ expectations of $0.63 million. As a group, sell-side analysts anticipate that Dianthus Therapeutics will post -2.32 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.